Please check your internet connection and try again.
# IV Dexamethasone
## Overview
A potent synthetic glucocorticoid with minimal mineralocorticoid activity. Displays significant anti-inflammatory and immunosuppressive properties. It has a long duration of action (biologic half-life 36–54 hours).
## Primary Indications
* Cerebral edema
* Acute anti-inflammatory/immunosuppressive therapy
* Antiemetic prophylaxis (chemotherapy-induced nausea and vomiting)
* Acute exacerbations of asthma or COPD
* Congenital adrenal hyperplasia (rarely IV)
* COVID-19 (severe/critical patients requiring supplemental oxygen)
## Adult Dosing
* **Cerebral Edema:** 10 mg IV bolus, followed by 4 mg IM/IV every 6 hours.
* **CINV Prophylaxis:** 8–20 mg IV once, depending on emetogenic potential of chemotherapy.
* **COVID-19:** 6 mg IV once daily for up to 10 days.
* **Acute Asthma/COPD:** 4–10 mg IV once or repeated every 12–24 hours until improvement.
## Pediatric Dosing
* **Cerebral Edema:** 1–2 mg/kg loading dose, then 1–1.5 mg/kg/day divided every 4–6 hours (max dose varies by institutional protocol).
* **Anti-inflammatory/Immunosuppressive:** 0.08–0.3 mg/kg/day IV divided every 6–12 hours.
* **Croup:** 0.6 mg/kg (single dose); maximum 10 mg.
* **COVID-19:** 0.15 mg/kg (max 6 mg) daily for 10 days.
## Dose Adjustments
* **Hepatic Impairment:** Clearance may be decreased; monitor for increased side effects.
* **Renal Impairment:** No specific adjustment required, but patients may be more sensitive to systemic effects.
* **Corticosteroid Tapering:** Required for long-term therapy (> 1–2 weeks) to avoid adrenal insufficiency.
## Contraindications
* Systemic fungal infections.
* Known hypersensitivity to dexamethasone or components (e.g., sulfites).
* Administration of live or attenuated vaccines while on immunosuppressive doses.
## Adverse Effects
* **Endocrine:** Hyperglycemia/diabetes mellitus, hypothalamic-pituitary-adrenal (HPA) axis suppression.
* **Gastrointestinal:** Peptic ulceration, GI bleeding (especially with concurrent NSAIDs).
* **Psychiatric:** Insomnia, mood swings, psychosis, agitation.
* **Musculoskeletal:** Delayed wound healing, osteoporosis, myopathy with chronic use.
* **Infection:** Increased susceptibility to bacterial, viral, or opportunistic infections.
## Key Drug Interactions
* **CYP3A4 Inducers (e.g., Phenytoin, Rifampin, Carbamazepine):** Decrease dexamethasone efficacy.
* **CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir):** Increase dexamethasone serum concentrations/toxicity.
* **NSAIDs:** Increased risk of GI ulceration/bleeding.
* **Antidiabetic agents:** Glucocorticoids antagonize hypoglycemic effects; dose adjustment of insulin/oral agents may be required.
## Monitoring
* Blood glucose (frequent monitoring in diabetics).
* Signs/symptoms of infection.
* Blood pressure and electrolyte status (hypokalemia).
* Psychiatric status (mood/behavior).
* Stool occult blood if chronic use is required.
## Clinical Pearls
* **Administration:** IV injection may be given undiluted; IV infusion should be diluted in D5W or NS.
* **Efficacy:** Dexamethasone is preferred for cerebral edema due to its potent anti-inflammatory CNS penetration.
* **HPA Axis:** Exogenous steroids can suppress adrenal response; taper gradually after withdrawal from long-term treatment.
* **Pediatrics:** Monitor growth velocity in children with long-term usage.
* **Note:** Always consult institutional guidelines for specific clinical pathways, as dosing for indications like meningitis or pediatric COVID-19 may vary significantly by protocol.
***
*Disclaimer: This information is for educational purposes only. Always verify current prescribing information, institutional guidelines, and drug compatibility via official package inserts or clinical resources (such as Lexicomp or Micromedex) before administration.*
